[{"orgOrder":0,"company":"Validcare","sponsor":"Algernon NeuroScience","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Partnership","leadProduct":"Dimethyltryptamine","moa":"5-HT1A\/2A\/2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Validcare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Validcare \/ Algernon NeuroScience","highestDevelopmentStatusID":"6","companyTruncated":"Validcare \/ Algernon NeuroScience"}]

Find Clinical Drug Pipeline Developments & Deals by Validcare

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Biotech Digital Meet
                          Not Confirmed
                          Biotech Digital Meet
                          Not Confirmed

                          Details : The partnership aims to advance the clinical development of company's mid-stage product AP-188 (dimethyltryptamine). It is being evaluated for stroke and traumatic brain injury.

                          Product Name : AP-188

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          February 05, 2025

                          Lead Product(s) : Dimethyltryptamine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Algernon NeuroScience

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank